Growth Factors of Contract Development and Manufacturing Organization (CDMO) Market
The Contract Development and Manufacturing Organization (CDMO) market size was valued at USD 224.86 billion in 2023, and the market is now projected tgrow from USD 242.62 billion in 2024 tUSD 465.14 billion by 2032, exhibiting a CAGR of 8.5% during the forecast period of 2024-2032.
Due tthe COVID-19 pandemic, the Contract Development and Manufacturing Organization (CDMO) market growth showed a barely mild advantageous growth in 2020 compared tthe preceding 12 months. As a result of this pandemic, the progress of drug development became impeded within the first half of the financial 12 months of 2020. However, many biopharmaceutical and pharmaceutical enterprise gamers ramped up their research and manufacturing efforts in the latter part of 2020 tcreate and distribute testing kits, vaccines, and medications for the SARS-CoV-2 virus.
The Contract Development and Manufacturing Organization (CDMO) market share is growing with the number of continual diseases growing globally due tthe populace boom, Western lifestyle adoption, and financial improvement. Pharmaceutical companies are more and more developing powerful scientific products tspeed up remedies due tthe boom in continual sicknesses and the growing older populace. Moreover, the ability of CDMOs toffer one-forestall-shop offerings inside the production of biopharmaceutical merchandise is one of the elements anticipated tcontribute tthe global Contract Development and Manufacturing Organization (CDMO) market increase at some point in the forecast period.
Additionally, the competitive panorama of the market for Contract Development and Manufacturing Organization (CDMO) is fragmented. Pharmaceutical organisations are largely specialised in offering speedy improvements tenhance the drug improvement and manufacturing process.
Comprehensive Analysis of Contract Development and Manufacturing Organization (CDMO) Market
The Contract Development and Manufacturing Organization (CDMO) market is segmented intContract Manufacturing Organization (CMO) and Contract Research Organization (CRO) services. The CMO phase, leading in 2023, includes API manufacturing, completed product production (extensively injectables), and packaging, with API production riding increase due trising biologics demand. The CRO section contains early-section improvement services, clinical trials, laboratory offerings, and others, with early-section offerings dominating in 2023 due tadvancements like in-silictechnology and increasing preclinical research. Clinical trials are alsgrowing gradually, supported by growing outsourcing and Research and Development investments in prescribed drugs and biotechnology.
North America held the biggest market share by producing sales of USD 87.03 billion in 2023. Throughout the forecast duration, the vicinity is anticipated tmaintain a leading role within the marketplace. The boom of the market is especially attributed tthe presence of properly hooked-up CDMOs in this vicinity.
The Contract Development and Manufacturing Organization (CDMO) market is fashioned by using key gamers, inclusive of IQVIA (U.S.), ICON per cent (Ireland), Syneos Health (U.S.), Vetter (Germany), Parexel International (MA) Corporation (U.S.), Recipharm AB (Sweden), and Curia Global, Inc. (U.S.), each contributing thru specialised offerings in scientific trials, manufacturing, and studies across worldwide markets. These groups are riding innovation and performance, addressing the developing demand for outsourced pharmaceutical and biotechnology solutions.
In February 2024 - NovHoldings introduced the purchase of Catalent, Inc., a settlement improvement production company, at USD 16.5 billion.
Segmentation Table
Global Contract Development and Manufacturing Organization (CDMO) Market Scope
Study Period 2019-2032
Base Year 2023
Forecast Period 2024-2032
Growth Rate CAGR of 8.5% from 2024-2032
Historical Period 2019-2022
Unit Value (USD Billion)
Segmentation By service, and Region
By service
CMO
- Solid Dosage Forms
- Injectables
- Others
- API Manufacturing
- Finished Product Manufacturing
- Packaging
CRO
- Chemistry, Manufacturing and Controls (CMC)
- Preclinical Service
- Discovery
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- Early Phase Development Services
- Clinical
- Laboratory Service
- Others
By Region
North America (By Service and Country)
- U.S.
- Canada
Europe (By Service and Country/Sub-Region)
- U.K.
- Germany
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
Asia Pacific (By Service and Country/Sub-Region)
- China
- Japan
- India
- Australia & New Zealand
- Rest of Asia Pacific
Rest of the World (By Service)
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 4. Key Insights
- 4.1. Number of Clinical Trials Conducted by Key Countries/ Sub-Region, 2022
- 4.2. Overview: Start-ups and Innovations in the Contract Development and Manufacturing Organization (CDMO) Market
- 4.3. Overview on Outsourcing of R&D, by Key Pharmaceutical Companies
- 4.4. R&D Investments, by Key Pharmaceutical and Biotechnological Companies
- 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
- 4.6. Impact of COVID-19 on the Market
- 5. Global Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2032
- 5.1. Market Analysis, Insights and Forecast – By Service
- 5.1.1. CMO
- 5.1.1.1. API Manufacturing
- 5.1.1.2. Finished Product Manufacturing
- 5.1.1.2.1. Solid Dosage Forms
- 5.1.1.2.2. Injectables
- 5.1.1.2.3. Others
- 5.1.1.3. Packaging
- 5.1.2. CRO
- 5.1.2.1. Early Phase Development Services
- 5.1.2.1.1. Chemistry, Manufacturing and Controls (CMC)
- 5.1.2.1.2. Preclinical Service
- 5.1.2.1.3. Discovery
- 5.1.2.2. Clinical
- 5.1.2.2.1. Phase 1
- 5.1.2.2.2. Phase 2
- 5.1.2.2.3. Phase 3
- 5.1.2.2.4. Phase 4
- 5.1.2.3. Laboratory Service
- 5.1.2.4. Others
- 5.2. Market Analysis, Insights and Forecast – By Region
- 5.2.1. North America
- 5.2.2. Europe
- 5.2.3. Asia Pacific
- 5.2.4. Rest of the World
- 6. North America Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast – By Service
- 6.1.1. CMO
- 6.1.1.1. API Manufacturing
- 6.1.1.2. Finished Product Manufacturing
- 6.1.1.2.1. Solid Dosage Forms
- 6.1.1.2.2. Injectables
- 6.1.1.2.3. Others
- 6.1.1.3. Packaging
- 6.1.2. CRO
- 6.1.2.1. Early Phase Development Services
- 6.1.2.1.1. Chemistry, Manufacturing and Controls (CMC)
- 6.1.2.1.2. Preclinical Service
- 6.1.2.1.3. Discovery
- 6.1.2.2. Clinical
- 6.1.2.2.1. Phase 1
- 6.1.2.2.2. Phase 2
- 6.1.2.2.3. Phase 3
- 6.1.2.2.4. Phase 4
- 6.1.2.3. Laboratory Service
- 6.1.2.4. Others
- 6.2. Market Analysis, Insights and Forecast – By Country
- 6.2.1. U.S.
- 6.2.2. Canada
- 7. Europe Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast – By Service
- 7.1.1. CMO
- 7.1.1.1. API Manufacturing
- 7.1.1.2. Finished Product Manufacturing
- 7.1.1.2.1. Solid Dosage Forms
- 7.1.1.2.2. Injectables
- 7.1.1.2.3. Others
- 7.1.1.3. Packaging
- 7.1.2. CRO
- 7.1.2.1. Early Phase Development Services
- 7.1.2.1.1. Chemistry, Manufacturing and Controls (CMC)
- 7.1.2.1.2. Preclinical Service
- 7.1.2.1.3. Discovery
- 7.1.2.2. Clinical
- 7.1.2.2.1. Phase 1
- 7.1.2.2.2. Phase 2
- 7.1.2.2.3. Phase 3
- 7.1.2.2.4. Phase 4
- 7.1.2.3. Laboratory Service
- 7.1.2.4. Others
- 7.2. Market Analysis, Insights and Forecast – By County/ Sub-region
- 7.2.1. Germany
- 7.2.2. U.K.
- 7.2.3. France
- 7.2.4. Italy
- 7.2.5. Spain
- 7.2.6. Scandinavia
- 7.2.7. Rest of Europe
- 8. Asia Pacific Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast – By Service
- 8.1.1. CMO
- 8.1.1.1. API Manufacturing
- 8.1.1.2. Finished Product Manufacturing
- 8.1.1.2.1. Solid Dosage Forms
- 8.1.1.2.2. Injectables
- 8.1.1.2.3. Others
- 8.1.1.3. Packaging
- 8.1.2. CRO
- 8.1.2.1. Early Phase Development Services
- 8.1.2.1.1. Chemistry, Manufacturing and Controls (CMC)
- 8.1.2.1.2. Preclinical Service
- 8.1.2.1.3. Discovery
- 8.1.2.2. Clinical
- 8.1.2.2.1. Phase 1
- 8.1.2.2.2. Phase 2
- 8.1.2.2.3. Phase 3
- 8.1.2.2.4. Phase 4
- 8.1.2.3. Laboratory Service
- 8.1.2.4. Others
- 8.2. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 8.2.1. China
- 8.2.2. India
- 8.2.3. Japan
- 8.2.4. Australia & New Zealand
- 8.2.5. Rest of Asia Pacific
- 9. Rest of the World Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast – By Service
- 9.1.1. CMO
- 9.1.1.1. API Manufacturing
- 9.1.1.2. Finished Product Manufacturing
- 9.1.1.2.1. Solid Dosage Forms
- 9.1.1.2.2. Injectables
- 9.1.1.2.3. Others
- 9.1.1.3. Packaging
- 9.1.2. CRO
- 9.1.2.1. Early Phase Development Services
- 9.1.2.1.1. Chemistry, Manufacturing and Controls (CMC)
- 9.1.2.1.2. Preclinical Service
- 9.1.2.1.3. Discovery
- 9.1.2.2. Clinical
- 9.1.2.2.1. Phase 1
- 9.1.2.2.2. Phase 2
- 9.1.2.2.3. Phase 3
- 9.1.2.2.4. Phase 4
- 9.1.2.3. Laboratory Service
- 9.1.2.4. Others
- 10. Competitive Analysis
- 10.1. Global Market Share Analysis (2023)
- 10.2. Company Profiles
- 10.2.1. IQVIA
- 10.2.1.1. Overview
- 10.2.1.2. Products & services
- 10.2.1.3. SWOT Analysis
- 10.2.1.4. Recent Developments
- 10.2.1.5. Strategies
- 10.2.1.6. Financials (Based on Availability)
- 10.2.2. ICON plc
- 10.2.2.1. Overview
- 10.2.2.2. Products & services
- 10.2.2.3. SWOT Analysis
- 10.2.2.4. Recent Developments
- 10.2.2.5. Strategies
- 10.2.2.6. Financials (Based on Availability)
- 10.2.3. Syneos Health
- 10.2.3.1. Overview
- 10.2.3.2. Products & services
- 10.2.3.3. SWOT Analysis
- 10.2.3.4. Recent Developments
- 10.2.3.5. Strategies
- 10.2.3.6. Financials (Based on Availability)
- 10.2.4. Vetter
- 10.2.4.1. Overview
- 10.2.4.2. Products & services
- 10.2.4.3. SWOT Analysis
- 10.2.4.4. Recent Developments
- 10.2.4.5. Strategies
- 10.2.4.6. Financials (Based on Availability)
- 10.2.5. Parexel International (MA) Corporation
- 10.2.5.1. Overview
- 10.2.5.2. Products & services
- 10.2.5.3. SWOT Analysis
- 10.2.5.4. Recent Developments
- 10.2.5.5. Strategies
- 10.2.5.6. Financials (Based on Availability)
- 10.2.6. Recipharm AB
- 10.2.6.1. Overview
- 10.2.6.2. Products & services
- 10.2.6.3. SWOT Analysis
- 10.2.6.4. Recent Developments
- 10.2.6.5. Strategies
- 10.2.6.6. Financials (Based on Availability)
- 10.2.7. Curia Global, Inc.
- 10.2.7.1. Overview
- 10.2.7.2. Products & services
- 10.2.7.3. SWOT Analysis
- 10.2.7.4. Recent Developments
- 10.2.7.5. Strategies
- 10.2.7.6. Financials (Based on Availability)
- 10.2.8. Thermo Fisher Scientific Inc.
- 10.2.8.1. Overview
- 10.2.8.2. Products & services
- 10.2.8.3. SWOT Analysis
- 10.2.8.4. Recent Developments
- 10.2.8.5. Strategies
- 10.2.8.6. Financials (Based on Availability)
- 10.2.9. Unither
- 10.2.9.1. Overview
- 10.2.9.2. Products & services
- 10.2.9.3. SWOT Analysis
- 10.2.9.4. Recent Developments
- 10.2.9.5. Strategies
- 10.2.9.6. Financials (Based on Availability)
- 10.2.10. DPT Laboratories, LTD.
- 10.2.10.1. Overview
- 10.2.10.2. Products & services
- 10.2.10.3. SWOT Analysis
- 10.2.10.4. Recent Developments
- 10.2.10.5. Strategies
- 10.2.10.6. Financials (Based on Availability)
- 10.2.11. NextPharma Technologies
- 10.2.11.1. Overview
- 10.2.11.2. Products & services
- 10.2.11.3. SWOT Analysis
- 10.2.11.4. Recent Developments
- 10.2.11.5. Strategies
- 10.2.11.6. Financials (Based on Availability)
- 10.2.12. Lonza
- 10.2.12.1. Overview
- 10.2.12.2. Products & services
- 10.2.12.3. SWOT Analysis
- 10.2.12.4. Recent Developments
- 10.2.12.5. Strategies
- 10.2.12.6. Financials (Based on Availability) "
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook